Chiron Real Estate (XRN) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
7 May, 2026Mission and strategy
Focuses on earnings growth and dividend stability by maximizing investment spread in healthcare real estate assets.
Invests primarily in off-campus, outpatient, and post-acute inpatient medical facilities.
Targets properties with attractive capitalization rates and strong, profitable tenants.
Leverages an experienced management team to maximize investor returns.
Recent business activity
Acquired $80.3 million in properties YTD 2024, totaling 15 properties and 254,220 leasable square feet at an 8.0% cap rate.
Under contract to acquire a five-property portfolio for $69.6 million at a 9.0% cap rate, expected to close in 2025.
Disposed of three properties for $20.2 million in gross proceeds.
Signed a new 15-year lease at Beaumont, TX, with $2.9 million annual base rent and 2.5% annual increases.
Raised $12 million by issuing 1.2 million shares at $9.95 per share in Q3 2024.
Portfolio and performance metrics
Market cap of $0.6B and $1.4B in gross real estate investments as of September 30, 2024.
Weighted average cap rate of 7.7% and dividend yield of 9.4%.
4.8M net leasable square feet across 187 buildings with 275 tenants and 96.1% occupancy.
Weighted average rent coverage of 4.6x, rent escalations of 2.2%, and lease term of 5.6 years.
Latest events from Chiron Real Estate
- $425M senior housing deals, $100M new capital, and 36% dividend cut drive growth shift.XRN
Q1 20268 May 2026 - Strategic acquisitions and a diversified portfolio drive growth and support a well-covered dividend.XRN
Investor presentation7 May 2026 - Virtual annual meeting set for May 20, 2026, with key votes on directors, pay, and auditor.XRN
Proxy filing8 Apr 2026 - Annual meeting to vote on directors, compensation, equity plan, and auditor, with enhanced governance.XRN
Proxy filing8 Apr 2026 - Strategic shift to senior housing, strong NOI growth, and 2026 Core FFO guidance of $4.30–$4.45.XRN
Q4 202526 Feb 2026 - Q2 net loss from property sale, but occupancy and AFFO remain strong; acquisitions ongoing.XRN
Q2 20242 Feb 2026 - Q3 2024 featured resilient occupancy, major acquisitions, and new leasing amid lower earnings.XRN
Q3 202416 Jan 2026 - Q4 2024 saw strong net income, stable AFFO, and growth via acquisitions and a new joint venture.XRN
Q4 20242 Dec 2025 - Annual meeting to vote on directors, pay, auditor; 2024 saw acquisitions and ESG progress.XRN
Proxy Filing2 Dec 2025